首页> 外文期刊>Expert opinion on investigational drugs >Erratum: Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection (Expert Opinion on Investigational Drugs (2012) 21(6) (773-783))
【24h】

Erratum: Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection (Expert Opinion on Investigational Drugs (2012) 21(6) (773-783))

机译:勘误:完全切除后,用Hyper-IL-6修饰的同种异体全细胞疫苗免疫的高危黑色素瘤患者的长期生存(Expert Opinion on Researchal Drugs(2012)21(6)(773-783))

获取原文
获取原文并翻译 | 示例
           

摘要

In the original research article entitled "Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection" by Andrzej Mackiewicz, Jacek Mackiewicz, Piotr J. Wysocki, Maciej Wiznerowicz, Malgorzata Kapcinska, Maria Laciak, Stefan Rose-John, Dariusz Izycki, Tomasz Burzykowski & Aldona Karczewska-Dzionk published in the June 2012 issue of Expert Opinion on Investigational Drugs (Expert Opin. Investig. Drugs (2012) 21(6): 773-783), the authors would like to correct an error in Figure 1.
机译:在Andrzej Mackiewicz,Jacek Mackiewicz,Piotr J. Wysocki,Maciej Wiznerowicz题为“完全切除后用Hyper-IL-6修饰的同种异体全细胞疫苗免疫的高危黑色素瘤患者的长期生存”的原始研究文章中,Malgorzata Kapcinska,Maria Laciak,Stefan Rose-John,Dariusz Izycki,Tomasz Burzykowski和Aldona Karczewska-Dzionk发表在2012年6月发行的《关于研究药物的专家意见》(专家意见,调查药物(2012)21(6):773) -783),作者想纠正图1中的错误。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号